Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug
1. Revolution Medicines reports positive Phase 1 results for daraxonrasib in PDAC. 2. Objective response rates were 35% and 29% for 2L patients with RAS mutations. 3. Analysts raised price targets, indicating strong confidence in RVMD's future. 4. Stock price surged 12.34% after trial updates. 5. Ongoing Phase 3 RASolute 302 trial expects data in 2026.